相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer
John Hang Leung et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)
Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
Dan Su et al.
FRONTIERS IN PHARMACOLOGY (2021)
Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
Li-Jen Cheng et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
Antonio Olry de Labry Lima et al.
BREAST (2021)
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
David S. P. Tan et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2021)
A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes
Yilin Yoshida et al.
CURRENT DIABETES REPORTS (2020)
Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service
Patrizio Armeni et al.
CLINICAL THERAPEUTICS (2020)
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis
David A. Barrington et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Wei Gao et al.
PHARMACOECONOMICS (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
Mei Zhan et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States
Courtney A. Penn et al.
JAMA NETWORK OPEN (2020)
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Bin Wu et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Dominic Muston et al.
GYNECOLOGIC ONCOLOGY (2020)
Cost-effectiveness analysis comparing PARP inhibitors-for-all to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer
Rafael Gonzalez et al.
GYNECOLOGIC ONCOLOGY (2020)
US Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer A Cost-Effectiveness Analysis
Joseph A. Dottino et al.
OBSTETRICS AND GYNECOLOGY (2019)
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Xuan Jiang et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer
Shota Saito et al.
PERSONALIZED MEDICINE (2019)
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
Holly Guy et al.
PHARMACOECONOMICS (2019)
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Prashanth Rawla et al.
WORLD JOURNAL OF ONCOLOGY (2019)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Lixian Zhong et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Vivek Verma et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Tarra Evans et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy
J. J. Wallbillich et al.
GYNECOLOGIC ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
Haller J. Smith et al.
GYNECOLOGIC ONCOLOGY (2015)
Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer
Darius N. Lakdawalla et al.
JAMA ONCOLOGY (2015)
An update on PARP inhibitors-moving to the adjuvant setting
Amir Sonnenblick et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Beyond breast and ovarian cancers: PARP BRCA mutation-associated and BRCA-like inhibitors for solid tumors
Clara C. O'Sullivan et al.
FRONTIERS IN ONCOLOGY (2014)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Don Husereau et al.
BMC MEDICINE (2013)
Cost-Effectiveness of BRCA1 and BRCA2 Mutation Testing to Target PARP Inhibitor Use in Platinum-Sensitive Recurrent Ovarian Cancer
Angeles Alvarez Secord et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
分享论文
